Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Toronto

$27,000.00

Splicing Gated Activation of SRRM4 as a Targeted Gene Therapy Approach for ASD

FY 2025-26

Summary
Autism spectrum disorder (ASD) is a neurodevelopmental condition defined by social challenges and repetitive actions. “Profound autism” is a subset of ASD defined as having non-to minimal verbal capabilities or an IQ below 50. In 2016, about 1 in 54 8-year-olds in the U.S. were identified with ASD, with 26.7% diagnosed with profound autism. In about one-third of individuals with ASD, neuronal microexons controlled by SRRM4 and other regulators display increased skipping. These changes have been linked to ASD-associated phenotypes in several mouse model studies. Microexons are tiny gene fragments that finetune the resulting RNA and are important for neuronal development and function. However, developing therapies to improve the quality of life for people living with ASD is challenging because typical gene therapies are “always on”, affecting all cells they are delivered into. In ASD, however, only some neurons show molecular abnormalities, meaning that an “always on” therapy could also harm healthy cells and cause unintended side effects. I aim to design a smarter gene therapy, delivering a shortened SRRM4 protein whose production is activated by the splicing abnormalities in affected cells. Building on a successful proof-of-concept from the Blencowe lab, I will create an efficient and compact version by studying which parts of SRRM4 are crucial for different aspects of its function. I will then develop lab-grown cerebral organoids (CO; “mini-brains” made from stem cells) and test the therapy in the COs and in SRRM4-deficient mice. If successful, my work could offer potential treatment for ASD and provide a template for the creation of therapies for other diseases linked to errors in RNA splicing, such as schizophrenia, retinal degeneration, and some cancers.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
573054
Name
Porat Dvir D
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Splicing Gated Activation of SRRM4 as a Targeted Gene Therapy Approach for ASD
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Autism Spectrum Disorder; Brain; Cerebral Organoids; Gene-Therapy; Microexon; Presicion Therapy; Rna Therapy; Splicing Gated Constructs; Srrm4; Therapy
Abstract
Autism spectrum disorder (ASD) is a neurodevelopmental condition defined by social challenges and repetitive actions. “Profound autism” is a subset of ASD defined as having non-to minimal verbal capabilities or an IQ below 50. In 2016, about 1 in 54 8-year-olds in the U.S. were identified with ASD, with 26.7% diagnosed with profound autism. In about one-third of individuals with ASD, neuronal microexons controlled by SRRM4 and other regulators display increased skipping. These changes have been linked to ASD-associated phenotypes in several mouse model studies. Microexons are tiny gene fragments that finetune the resulting RNA and are important for neuronal development and function. However, developing therapies to improve the quality of life for people living with ASD is challenging because typical gene therapies are “always on”, affecting all cells they are delivered into. In ASD, however, only some neurons show molecular abnormalities, meaning that an “always on” therapy could also harm healthy cells and cause unintended side effects. I aim to design a smarter gene therapy, delivering a shortened SRRM4 protein whose production is activated by the splicing abnormalities in affected cells. Building on a successful proof-of-concept from the Blencowe lab, I will create an efficient and compact version by studying which parts of SRRM4 are crucial for different aspects of its function. I will then develop lab-grown cerebral organoids (CO; “mini-brains” made from stem cells) and test the therapy in the COs and in SRRM4-deficient mice. If successful, my work could offer potential treatment for ASD and provide a template for the creation of therapies for other diseases linked to errors in RNA splicing, such as schizophrenia, retinal degeneration, and some cancers.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Porat, Dvir D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~